Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee
Abstract A wide variety of new therapeutic options for Multiple Myeloma (MM) have recently become available, extending progression-free and overall survival for patients in meaningful ways. However, these treatments are not curative, and patients eventually relapse, necessitating decisions on the ap...
Main Authors: | Shaji Kumar, Lawrence Baizer, Natalie S. Callander, Sergio A. Giralt, Jens Hillengass, Boris Freidlin, Antje Hoering, Paul G. Richardson, Elena I. Schwartz, Anthony Reiman, Suzanne Lentzsch, Philip L. McCarthy, Sundar Jagannath, Andrew J. Yee, Richard F. Little, Noopur S. Raje |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2022-06-01
|
Series: | Blood Cancer Journal |
Online Access: | https://doi.org/10.1038/s41408-022-00695-5 |
Similar Items
-
Bone Disease in Multiple Myeloma: Biologic and Clinical Implications
by: Zachary S. Bernstein, et al.
Published: (2022-07-01) -
Treatment of Smoldering Multiple Myeloma: Ready for Prime Time?
by: E. Bridget Kim, et al.
Published: (2020-05-01) -
Lifestyle considerations in multiple myeloma
by: Yael N. Shapiro, et al.
Published: (2021-10-01) -
Proteasome inhibition and its therapeutic potential in multiple myeloma
by: Ajai Chari, et al.
Published: (2010-09-01) -
Extramedullary disease in multiple myeloma
by: Radhika Bansal, et al.
Published: (2021-09-01)